Drug-induced hepatotoxicity in humans

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 1, 2008, Pages 53-59

  Halegoua De Marzio, D ^a   Navarro, V J ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Biomarkers; Drug hepatitis; Hepatotoxicity; Liver injury; Metabonomics; Pharmacogenomics; Proteonomics

Indexed keywords

ACARBOSE; ALLOPURINOL; AMFEBUTAMONE; AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIRETROVIRUS AGENT; AZATHIOPRINE; CARBAMAZEPINE; CLINDAMYCIN; CLOPIDOGREL; CYPROHEPTADINE; ERYTHROMYCIN; FLUOXETINE; FLUTAMIDE; IRBESARTAN; ISONIAZID; KAVA; KETOCONAZOLE; METHOTREXATE; MIRTAZAPINE; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; SULFANILAMIDE DERIVATIVE; SULFONAMIDE; TERBINAFINE; TRICYCLIC AROMATIC COMPOUND; TRIMETHOPRIM; UNINDEXED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; CLINICAL FEATURE; HUMAN; LABORATORY DIAGNOSIS; LIVER INJURY; LIVER TOXICITY; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HEPATITIS, TOXIC; HUMANS; METABOLISM; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PROTEOMICS; SAFETY;

EID: 37849028712     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Lee WM: Drug-induced hepatotoxicity. N Engl J Med (2003) 349(5):474-485. •• Provides an in-depth review of the mechanisms of drug-induced hepatotoxicity.
2. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: New estimates of drug development costs. J Health Econ (2003) 22(2):151-185.
3. Adams CP, Branter VV: Estimating the cost of new drug development: Is it really $802 million? Health Aff (2006) 25(2):420- 428.
4. Challenge and opportunity on the critical path to new medical therapy: US Food & Drug Administration, Rockville, MD, USA (2004). http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
5. Frank R, Hargreaves R: Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov (2003) 2(7):566-580. • Provides an overview of current research in the field of biomarkers for detecting drug toxicity in the drug-development phase.
6. Kaplowitz N: Drug-induced liver injury. Clin Infect Dis (2004) 38(Suppl 2):S44-S48. • Provides an overview of the clinical presentation, pathogenesis and areas of future research in the field of drug-induced hepatoxicity.
7. Navarro VJ, Senior JR: Drug-related hepatotoxicity. N Engl J Med (2006) 354(7):731-739. •• Provides a comprehensive review of current mechanisms of detection and patterns of drug-induced hepatoxicity.
8. Chitturi, S, Farrell GC: Herbal hepatotoxicity: An expanding but poorly defined problem. J Gastroenterol Hepatol (2000) 15(10):1093-1099.
9. Neuberger J: Drug-induced jaundice. Bailliere's Clin Gastroenterol (1989) 3(2):447-466.
10. Maddrey WC: Drug-induced hepatotoxicity 2005. J Clin Gastroenterol (2005) 39(Suppl 2):S83-S89.
11. Danan G, Benichou C: Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol (1993) 46(11):1323-1330.
12. Benichou C, Danan G, Flahault A: Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. J Clin Epidemiol (1993) 46(11):1331-1336.
13. Maria VA, Victorino RM: Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology (1997) 26(3):664-669.
14. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F: Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology (2001) 33(1):123-130.
15. Lee WM, Senior JR: Recognizing drug-induced liver injury: Current problems, possible solutions. Toxicol Pathol (2005) 33(1):155-164. • Examines the process of establishing whether a case of liver disease was caused by a particular drug, and makes suggestions as to how to determine the true incidence of, and clinical risk factors for, drug-induced hepatotoxicity.
16. Hoofnagle JH: Drug-Induced Liver Injury Network (DILIN). Hepatology (2004) 40(4):773. • Describes the focus and goals of research currently being carried out by the DILIN.
17. CDER-PhRMA-AASLD conference 2000: Clinical white paper on drug-induced hepatotoxicity: US Food & Drug Administration, Rockville, MD, USA (2000). http://www.fda.gov/cder/livertox/clinical. pdf
18. Nolan CM, Goldberg SV, Buskin SE: Hepatotoxicity associated with isoniazid preventative therapy: A 7 year survey from a public health tuberculosis clinic. J Am Med Assoc (1999) 281(11):1014-1018.
19. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. J Am Med Assoc (1994) 271(13):992-998.
20. Zimmerman HJ (Ed): Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Appleton-Century-Crofts, New York, NY, USA (1978).
21. Gale E: Lessons from the glitazones: A story of drug development. Lancet (2001) 357(9271):1870-1875.
22. Chojkier M: Troglitazone and liver injury: In search of answers. Hepatology (2005) 41(2):237-246.
23. Lewis JH: 'Hy's law', the 'Rezulin rule,' and other predictors of severe drug-induced hepatotoxicity: Putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf (2006) 15(4):221-229.
24. Evans W, McLeod H: Pharmacogenomics - drug disposition, drug targets and side effects. N Engl J Med (2003) 348(6):538-549. • Focuses on the therapeutic consequences of inherited differences in drug disposition and drug targets.
25. Wilkinson G: Drug metabolism and variability among patients in drug response. N Engl J Med (2005) 352(21):2211-2221. • Considers the many differences among patients in terms of the disposition and clinical consequences of drugs resulting from differences in CYP enzymes.
26. Kimura S, Umeno M, Skoda, RC, Meyer UA, Gonzalez FJ: The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am J Hum Genet (1989) 45(6):889-904.
27. Larrey D, Pageaux G: Genetic predisposition to drug-induced hepatotoxicity. J Hepatol (1997) 26(Suppl 2):12-21.
28. Weinshilboum R: Inheritance and drug response. N Engl J Med (2003) 348(6):529-537. •• Expands on the study of pharmacogenetics and the importance of the relationship between inheritance and variation in drug response.
29. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 353(9154):717-719.
30. Spielberg SP: In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans. Fed Proc (1984) 43(8):2308-2313.
31. Huang YS, Su WJ, Huang YH, Chen CY, Chang FY, Lin HC, Lee SD: Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol (2007) 47(1):128-134.
32. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP: Genetic susceptibility to diclofenac-induced hepatotoxicity: Contribution of UGT2B7, CYP2C8 and ABCC2 genotypes. Gastroenterology (2007) 132(1):272-281.
33. Amacher DE, Adler R, Herath A, Townsend RR: Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy. Clin Chem (2005) 51(10):1796-1803. •• Provides a review that identifies serum marker proteins in rats, which might serve as sensitive indicators of hepatomegaly, hepatocellular necrosis or hepatobiliary injury.
34. Raucy JL, Ingelman-Sundberg M, Carpenter S, Rannug A, Rane A, Franklin M, Romkes M: Drug metabolizing enzymes in lymphocytes. J Biochem Mol Toxicol (1999) 13(3-4):223-226.
35. Watkins PB, Seeff LB. Drug-induced liver injury: Summary of a single topic clinical research conference. Hepatology (2006) 43(3):618-631. •• Describes the current high-priority areas of the DILIN including novel data concerning hepatotoxicity.
36. Aleksunes LM, Manautou JE: Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. Toxicol Pathol (2007) 35(4):459-473.
37. Fukushima T, Kikkawa R, Hamada Y, Horii I: Genomic cluster and network analysis for predictive screening for hepatotoxicity. J Toxicol Sci (2006) 31(5):419-432. • Describes a study that considers the application of genomic approaches to predict drug hepatotoxicity, particularly cluster analysis for classification and early prediction of hepatotoxicity.
38. Lindon JC, Keun HC, Ebbels TM, Peare JM, Holmes E, Nicholson JK: The Consortium for Metabolic Toxicology (COMET): Aims, activities and achievements. Pharmacogenomics (2005) 6(7):691-699.
39. Walgren JL, Mitchell MD, Thompson DC: Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol (2005) 35(4):325-361.
40. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP: The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol (2005) 45:177-202.